Comparative study of Bifidobacterium animalis, Escherichia coli, Lactobacillus casei and Saccharomyces boulardii probiotic properties

Abstract

The present work investigates some probiotic properties of four different microorganisms (Bifidobacterium animalis var. lactis BB-12, Escherichia coli EMO, Lactobacillus casei and Saccharomyces boulardii). In vitro and in vivo tests were carried out to compare cell wall hydrophobicity, production of antagonistic substances, survival capacity in the gastrointestinal tract of germ-free mice without pathological consequence, and immune modulation by stimulation of Küpffer cells, intestinal sIgA and IL-10 levels. In vitro antagonism against pathogenic bacteria and yeast was only observed for the probiotic bacteria B. animalis and L. casei. The hydrophobic property of the cell wall was higher for B. animalis and E. coli EMO, and this property could be responsible for a better ability to colonize the gastrointestinal tract of germ-free mice. Higher levels of sIgA were observed mainly for S. boulardii, followed by E. coli EMO and B. animalis, and only S. boulardii induced a significant higher level of IL-10. In conclusion, for a probiotic use, S. boulardii presented better characteristics in terms of immunomodulation, and B. animalis and L. casei for antagonistic substance production. The knowledge of the different probiotic properties could be used to choice the better microorganism depending on the therapeutic or prophylactic application.

Evaluation of mucositis induced by irinotecan after microbial colonization in germ-free mice

“…Then, they were centrifuged (2000 g, 30 min, 4 uC) and the supernatant collected and frozen at 280 uC for later determination of immunoglobulins. The determination of total sIgA levels was performed by ELISA as previously described by Martins et al (2009).…”

Gleaning Insights from Fecal Microbiota Transplantation and Probiotic Studies for the Rational Design of Combination Microbial Therapies

“…Several studies have shown that the administration of probiotic organisms can increase total secretory IgA levels in rodents (148,(152)(153)(154), which may contribute to the control of C. difficile bacteria (72,(77)(78)(79)(80)(81). S. boulardii, for example, increases total secretory IgA levels in conventional rats and mice as well as in germfree mice colonized with S. boulardii (148,(152)(153)(154)(155). Studies of Bifidobacterium animalis subsp.…”

“…Studies of Bifidobacterium animalis subsp. lactis BB-12, Escherichia coli EMO, and Lactobacillus casei and L. rhamnosus strains showed effects on total secretory IgA levels in rodent models (153,(156)(157)(158). However, the mechanisms by which some probiotics increase secretory IgA levels are not well understood, and more studies are needed to determine whether such changes in antibody production could protect against CDI.…”

Functional Gastrointestinal Disorders in Infants: Causes of Occurrance, Diagnostic Criteria and Possibilities of Correction With Probiotics

“…Установлено, что данный пробиотический штамм: ■ способен к высокоуровневой адгезии к поверхностям с муцином, без муцина и пленкам клеточных культур [34]; ■ устойчив к действию агрессивных сред организма че-ловека -соляной кислоты и желчи, за счет синтеза рН-зависимой АТФ-азы, регулирующей кислотно-основ-ной баланс внутри бактерии и наличия гидролазы солей желчных кислот, позволяющей бактерии сохранять актив-ность в присутствии желчи [35] [36]; и резистентностью к таким антибиотикам, как гентамицин, стреп-томицин, полимиксин В, канамицин, нео мицин, циклосерин, тетрациклин и налидиксовая кислота [37] -способ-ствует улучшению барьерной функции кишечного эпителия (повышение кон-центрации секреторного IgA) [38,39] и положительно влияет на работу иммун-ной системы [40].…”